期刊文献+

非心源性休克患者脑钠肽与血流动力学参数的相关性分析及两者预测预后的价值探讨 被引量:6

The correlation between brain natriuretic peptide and invasive hemodynamic parameters and their value in prognosis of patients with noncardiac shock
原文传递
导出
摘要 目的探讨非心源性休克患者血浆脑钠肽(BNP)水平与肺动脉漂浮导管(Swan—Ganz导管)所测得数据的相关性,以及与患者预后的关系。方法采用前瞻性对照研究方法,选择本院重症监护病房(ICU)21例非心源性休克患者,置入Swan—Ganz导管,连续3d测定中心静脉压(CVP)、肺动脉压(PAP)、肺毛细血管楔压(PCWP)、心排血量(co),同时进行血浆BNP定量检测;分析存活患者(8例)和死亡患者(13例)BNP及CVP、PAP、PCWP、CO的差异。采用多元回归分析法分析BNP与CVP、PAP、PCWP、CO的相关性。结果死亡患者人院时血浆BNP浓度(ng/L)显著高于存活患者(708.06±242.58比317.05±140.21,P〈0.05):而两组患者血流动力学参数无明显差异。治疗3d后,死亡患者CVP(mmHg,1mmHg=0.133kPa)显著高于存活患者(13.64±4.00比9.92±1.26,P〈O.05),而CO(L/min)显著低于存活患者(4.61±2.06比6.95±1.28,P〈0.05),死亡患者和存活患者PAP(mmHg)、PCWP(mmHg)无明显差异(PAP:20.84±8.48比16.82±4.97,PCWP:13.60±5.71比12.72±4.98,均P〉0.05)。多元回归分析显示,BNP与CVP、PAP、PCWP、CO均无明显相关性(r值分别为0.157、0.306、0.229、-0.269,P值分别为0.16、0.25、0.09、0.12)。结论血浆BNP和Swan—Ganz导管监测血流动力学参数对休克患者病情和预后的评估均有一定价值;但在非心源性休克患者中,BNP增高不能作为反映心功能的指标,不能替代Swan—Ganz导管用于指导治疗。 Objective To examine the correlation between the plasma level of brain natriuretic peptide (BNP) and the hemodynamic parameters collected through Swan-Ganz flowing balloon catheter procedure in patients with noncardiac shock, in order to evaluate the potential for BNP to be used as prognostic indicator. Methods The plasma BNP and invasive hemodynamic parameters data [central venous pressure (CVP), pulmonary arterial pressure (PAP), pulmonary capillary wedge pressure (PCWP), and cardiac output (CO)1 were collected from 21 noncardiac shock patients received Swan-Ganz catheterization throughout a continuous surveillance for 3 days. The BNP, CVP, PAP, PCWP, CO in survivors (n = 8 ) and non-survivors (n=13 ) were compared and the correlation between the value of BNP and the invasive hemodynamic parameters were analyzed using multiple regression. Results The mean value of BNP (ng/L) was significantly higher in non-survivors (708.06 ± 242.58 vs. 317.05 ±140.21, P〈0.05). In day 1, no significant difference was found in any hemodynamic parameters between non-survivors and survivors. But in day 3, the non-survivors were found to have significantly higher CVP (mm Hg, 1 mm Hg=0.133 kPa: 13.64 ± 4.00 vs. 9.92 ± 1.26, P〈0.05) and lower CO (L/min: 4.61 ±2.06 vs. 6.95 ± 1.28, P〈0.05). The differences in PAP (mm Hg: 20.84 ± 8.48 vs. 16.82 ± 4.97) and PCWP (mm Hg: 13.60 ± 5.71 vs. 12.72 ±4.98) remained insignificant (both P〉 0.05 ) between the two groups. The correlation between BNP and the invasive hemodynamic parameters was modest there was no correlation between BNP and CVP, PAP, PCWP, CO (r=0.157, 0.306, 0.229, -0.269, P=0.16, 0.25, 0.09, 0.12). Conclusions In patients with shock, both plasma BNP and invasive hemodynamic examination showed certain prognostic value. But in noncardiac shock cases, the increased BNP did not correlate with heart function, therefore it could not replace the Swan-Ganz catheter data to guide the treatment in these patients.
出处 《中国危重病急救医学》 CAS CSCD 北大核心 2012年第1期54-56,共3页 Chinese Critical Care Medicine
基金 四川省医药卫生科研项目(100043) 四川省成都市医药卫生科研项目(0908)
关键词 Swan—Ganz导管 脑钠肽 休克 心源性 预后价值评估 Swan-Ganz flowing balloon catheter Brain natriuretic peptide Cardiogenic shock Prognostic value
  • 相关文献

参考文献10

  • 1Nossaman BD,Scruggs BA,Nossaman VE,et al. History of right heart catheterization : 100 years of experimentation and methodology development. Cardiol Rev, 2010,18:94-101.
  • 2Karmpaliotis D, Kirtane A J, Ruisi CP, et al. Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest, 2007,131 : 964-971.
  • 3李召辉,肖军,李金泽.血浆N末端B型钠尿肽前体对重症患者预后的预测价值研究[J].中国危重病急救医学,2011,23(3):179-182. 被引量:41
  • 4Sturgess D J, Marwick TH, Joyce C, et al. Prediction of hospital outcome in septic shock : a prospective comparison of tissue Doppler and cardiac biomarkers. Crit Care, 2010,14: R44.
  • 5Meaudre E, Jego C, Kenane N, et al. B-type natriuretic peptide release and left ventricular filling pressure assessed by echocardiographic study after subarachnoid hemorrhage: a prospective study in non-cardiac patients. Crit Care, 2009,13 : R76.
  • 6Banki NM, Kopelnik A, Dae MW, et al. Acute neurocardiogenic injury after subarachnoid hemorrhage. Circulation, 2005,112 : 3314-3319.
  • 7Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pulmonary artery catheter in critically ill patients:meta-analysis of randomized clinical trials. JAMA, 2005,294:1664-1670.
  • 8巫文丽,廖雪松,王伟,燕纯伯,蔡琳,王引利,何川,唐炯,刘汉雄,邓晓奇.BNP与有创血流动力学指标的相关性分析[J].四川医学,2008,29(7):838-839. 被引量:7
  • 9Fontana F,Bernardi P,Spagnolo N,et al. Plasma atrial natriuretic factor in patients with acute myocardial infarction. Eur Heart J, 1990,11:779-787.
  • 10黄永新,詹新华,郑静伟,吴祖煌,陈建崇,朱剑仙,谢包根,刘世康.严重延迟复苏烧伤休克患者血浆脑钠肽的变化[J].中国危重病急救医学,2010(6):354-357. 被引量:5

二级参考文献31

  • 1汪芳,王莉,边文彦,顼志敏,李一石.慢性心力衰竭急性发作患者N端前脑钠素水平的变化[J].中国危重病急救医学,2006,18(4):195-198. 被引量:21
  • 2夏照帆.严重烧伤后延迟复苏[J].继续医学教育,2006,20(14):13-16. 被引量:3
  • 3肖军,钟荣,叶桂山.APACHE、SAPS及LODS3种评分系统在单一重症监护室的应用比较[J].中国危重病急救医学,2006,18(12):743-747. 被引量:32
  • 4Gibran NS.Practice guidelines for burn care,2006.J Burn Care Res,2006,27:437-438.
  • 5Januzzi JL Jr, Richards AM. An international consensus statement regarding Amino-Terminal pro-B-type natriuretic peptide testing: the international NT-proBNP consensus panel. Am J Cardiol, 2008,101: 3A-5A.
  • 6de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet, 2003,362: 316-322.
  • 7Bajwa EK, Januzzi JL, Gong MN, et al. Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med, 2008,368 :2322-2327.
  • 8Varpula M, Pulkki K, Karlsson S, et al. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med, 2007,35:1277-1283.
  • 9Mokart D, Sannini A, Brun JP, et al. N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shock. Crit Care, 2007,112 :R37.
  • 10Tomaru Ki K, Arai M, Yokoyama T, et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes.J Mol Cell Cardiol, 2002,34: 649-659.

共引文献50

同被引文献69

  • 1马丽君(综述),秦英智(审校).血管外肺水的研究进展[J].中国危重病急救医学,2007,19(2):120-122. 被引量:24
  • 2Tang WH, Francis GS, Morrow DA, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem,2008,41 (4-5) : 210-221.
  • 3Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2005 : the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) . Eur J Heart Fail,2008,10 (10):933- 989.
  • 4Gale CP, White JE, Hunter A, et al. Predicting mortality and hospital admission in patients with COPD : significance of NT pro-BNP, clinical and echocardiographic assessment. J Cardiovasc Med ( Hagerstown ), 2011,12 ( 9 ) : 613-618.
  • 5Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation. J Am Coil Cardiol,2011,58 (16) : 1705-1714.
  • 6Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. Int Heart J, 2010, 51 (5) : 343-347.
  • 7Lowenthal A, Camaeho BV, Lowenthal S, et al. Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease. Am J Cardiol,2012,109 (6): 866-872.
  • 8Maisel A, Mueller C, Adams K Jr, et al. State of the art : using natriuretic peptide levels in clinical practice. Eur J Heart Fail, 2008,10 (9) : 824-839.
  • 9Noveanu M, Pargger H, Breidthardt T, et al. Use of B-type natriuretic peptide in the management of hypoxaemic respiratory failure. EurJ Heart Fail,2011,13 (2) : 154-162.
  • 10Yardan T, Altintop L, Baydin A, et al. B-type natriuretic peptide as an indicator of right ventricular dysfunction in acute pulmonary embo|ism. Int J Clin Praet, 2008,62 ( 8 ) : 1177-1182.

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部